NCT00491855View on ClinicalTrials.gov

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Peritoneal Cancer
Interventions
DRUG

Bevacizumab

Starting dose level 2.5 mg/kg given intravenously on day 1.

DRUG

Oxaliplatin

Starting dose level 25 mg/m\^2 given intraperitoneally on day 2.

DRUG

Paclitaxel

Starting dose level 110 mg/m\^2 given continuous infusion on day 1 and 30 mg/m\^2 given intraperitoneally on day 8.

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00491855 - Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis | Biotech Hunter | Biotech Hunter